||5R01CA097271-10 Interpret this number
||Fred Hutchinson Cancer Research Center
||Risk Factors for Second Primary Breast Cancer Among Dcis Survivors
The proposed study is a competitive renewal of our currently funded project that is investigating how
epidemiological factors, clinical and pathological characteristics, and tumor marker expression influence the
risk of second primary invasive contralateral breast cancer among survivors of a first primary invasive breast
cancer. Here we propose to expand this work by evaluating factors that are related to risk of second primary
breast cancers among ductal carcinoma in situ (DCIS) survivors. Incidence rates of DCIS have increased 7.2-
fold from 1980 to 2001 in the United States, largely as a result of widespread breast cancer screening. DCIS
lesions are very responsive to available therapies, and five-year disease-specific survival rates are close to
100%. However, DCIS survivors have a 3.4 to 8.6-fold higher risk of developing a second breast cancer
compared to the risk that women in the general population have of developing a first breast cancer. The recent
rapid rise in DCIS incidence rates has translated into a large and growing population of DCIS survivors who
are particularly susceptible to developing a second breast cancer. Not all DCIS patients will go on to develop a
second breast cancer, so certain surgical and adjuvant therapy combinations for DCIS constitute over-
treatment for those at low risk of a second breast cancer, while others constitute under-treatment for those at
high risk. At present, however, there is a lack of meaningful prognosticators to indicate which DCIS survivors
are at high or low risk of developing a second breast cancer. Such prognosticators could be important guides
to help these patients and their clinicians choose the most appropriate course of therapy and subsequent
follow-up care. We propose to investigate how epidemiological, clinical, and histopathological characteristics of
DCIS impact the risk of second primary breast cancers among DCIS survivors. We will recruit 515 patients
diagnosed with DCIS and a verified subsequent second primary in situ or invasive breast cancer, and a control
group consisting of 1,030 patients diagnosed only with DCIS to address the following specific aims: 1) How do
epidemiological risk factors for breast cancer, including reproductive characteristics, anthropometric measures,
use of exogenous hormones, mammographic density, and family history of breast cancer, influence the risks of
second primary breast cancer overall, contralateral second primary breast cancer, and ipsilateral second
primary breast cancer among DCIS survivors?; and 2) How do the clinical and histopathological features of
DCIS, including treatments, tumor grade, and histological subtype impact risks of second primary breast
cancer overall, contralateral second primary breast cancer, and ipsilateral second primary breast cancer
among DCIS survivors? The proposed study will provide important information to the rapidly growing
population of DCIS survivors as its results may help modulate their risk of developing a second primary breast
cancer and inform their decision-making regarding DCIS treatments and subsequent breast cancer screening.
If you are accessing this page during weekend or evening hours, the database may currently be offline for maintenance and should operational within a few hours. Otherwise, we have been notified of this error and will be addressing it immediately.
Please contact us
if this error persists.
We apologize for the inconvenience.
- The DCCPS Team.